Septerna, Inc. (SEPN)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGM
38.91 USD
-1.56
(-3.855%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 38.91 |
Hot Take ↕ | Aug. 22, 2026, 4 a.m. EDT
The investment case here is defined by a stark disconnect between explosive top-line growth and deteriorating profitability. Revenue surged 224% year-over-year, yet the company is burning cash with negative operating margins and a forward P/E that indicates no expected earnings for the foreseeable future. While the balance sheet remains healthy with a current ratio near 5.0 and manageable debt, the lack of free cash flow conversion creates a precarious runway for a biotech firm dependent on capital markets. The recent price action shows a volatile rebound from multi-month lows, trading well above its 200-day average, which suggests some short-covering or renewed interest in the pipeline catalysts. However, the options market tells a different story for the medium-to-long term: traders are aggressively buying deep out-of-the-money puts for delivery in early 2027, betting on a potential failure of the drug development cycle or a prolonged period of dilution. This heavy put positioning acts as a significant headwind, capping upside potential until the next major clinical readout provides definitive proof of commercial viability. Until the company demonstrates a path to profitability or secures substantial non-dilutive funding, the risk-reward profile remains skewed toward caution. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.092053 |
| AutoETS | 0.119192 |
| AutoARIMA | 0.119195 |
| MSTL | 0.122751 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.71 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.451 |
| Excess Kurtosis | -0.92 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.83 |
| Revenue per Share | 2.213 |
| Market Cap | 1,816,200,064 |
| Forward P/E | -20.05 |
| Profit Margins | -24.51% |
| Website | https://septerna.com |
As of Aug. 22, 2026, 4 a.m. EDT: Speculators are heavily positioning for downside protection over the long term, evidenced by massive open interest in January 2027 puts at strikes significantly below the current price (30.00 strike holds nearly 1,000 contracts). Conversely, call activity is sparse and concentrated near the money, suggesting limited speculative conviction in a near-term breakout despite elevated implied volatility on the short-dated side.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.2795787 |
| Address1 | 250 East Grand Avenue |
| All Time High | 51.1 |
| All Time Low | 4.17 |
| Ask | 49.92 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 378,910 |
| Average Daily Volume3 Month | 447,027 |
| Average Volume | 447,027 |
| Average Volume10Days | 378,910 |
| Bid | 28.35 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 8.426 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 38.91 |
| Current Ratio | 4.995 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 40.945 |
| Day Low | 38.74 |
| Debt To Equity | 5.83 |
| Display Name | Septerna |
| Earnings Timestamp End | 1,794,254,400 |
| Earnings Timestamp Start | 1,794,254,400 |
| Ebitda | -54,395,000 |
| Ebitda Margins | -0.55009997 |
| Enterprise To Ebitda | -28.297 |
| Enterprise To Revenue | 15.566 |
| Enterprise Value | 1,539,239,040 |
| Eps Current Year | -1.18679 |
| Eps Forward | -1.94098 |
| Eps Trailing Twelve Months | -0.53 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 37.2742 |
| Fifty Day Average Change | 1.6357994 |
| Fifty Day Average Change Percent | 0.043885566 |
| Fifty Two Week Change Percent | 227.95787 |
| Fifty Two Week High | 51.1 |
| Fifty Two Week High Change | -12.189999 |
| Fifty Two Week High Change Percent | -0.23855184 |
| Fifty Two Week Low | 11.98 |
| Fifty Two Week Low Change | 26.93 |
| Fifty Two Week Low Change Percent | 2.2479134 |
| Fifty Two Week Range | 11.98 - 51.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,729,863,000,000 |
| Float Shares | 26,409,817 |
| Forward Eps | -1.94098 |
| Forward P E | -20.046576 |
| Free Cashflow | 29,544,876 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 123 |
| Fullday Change | -1.56 |
| Fullday Change Percent | -3.85471 |
| Fullday Price | 38.91 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 1.0 |
| Gross Profits | 98,882,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.030669998 |
| Held Percent Institutions | 0.98692 |
| Implied Shares Outstanding | 46,676,947 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-10-25 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California. |
| Long Name | Septerna, Inc. |
| Market | us_market |
| Market Cap | 1,816,200,064 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1765584396 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -24,236,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,887,615,736 |
| Number Of Analyst Opinions | 9 |
| Open | 40.25 |
| Operating Cashflow | 106,007,000 |
| Operating Margins | -0.62948 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 650 338 3533 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 38.91 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 40.47 |
| Price Eps Current Year | -32.78592 |
| Price Hint | 2 |
| Price To Book | 4.61785 |
| Price To Sales Trailing12 Months | 18.367348 |
| Profit Margins | -0.2451 |
| Quick Ratio | 4.895 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.1 |
| Region | US |
| Regular Market Change | -1.56 |
| Regular Market Change Percent | -3.85471 |
| Regular Market Day High | 40.945 |
| Regular Market Day Low | 38.74 |
| Regular Market Day Range | 38.74 - 40.945 |
| Regular Market Open | 40.25 |
| Regular Market Previous Close | 40.47 |
| Regular Market Price | 38.91 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 385,854 |
| Return On Assets | -0.071339995 |
| Return On Equity | -0.06342 |
| Revenue Growth | 223.756 |
| Revenue Per Share | 2.213 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 46,676,947 |
| Shares Percent Shares Out | 0.0616 |
| Shares Short | 2,874,690 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 3,350,617 |
| Short Name | Septerna, Inc. |
| Short Percent Of Float | 0.1177 |
| Short Ratio | 7.05 |
| Source Interval | 15 |
| State | CA |
| Symbol | SEPN |
| Target High Price | 62.0 |
| Target Low Price | 48.0 |
| Target Mean Price | 54.22222 |
| Target Median Price | 51.0 |
| Total Cash | 372,321,984 |
| Total Cash Per Share | 7.977 |
| Total Debt | 22,545,000 |
| Total Revenue | 98,882,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.53 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 29.176676 |
| Two Hundred Day Average Change | 9.733324 |
| Two Hundred Day Average Change Percent | 0.33359948 |
| Type Disp | Equity |
| Volume | 385,854 |
| Website | https://septerna.com |
| Zip | 94,080 |